|
|
|
| Experimental study on the effect of progesterone receptor membrane component 1 on hormone-induced breast cancer proliferation |
| ZHAO Yue CHENG Jiaojiao |
| Department of Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China |
|
|
|
Abstract Objective To investigate the effect of progesterone receptor membrane component 1 (PGRMC1) on hormone-induced breast cancer proliferation. Methods On the basis of in vitro studies, 36 BALB/c-nu female nude mice were selected and divided into the stable expression of PGRMC1 (T47D/HA-PGRMC1) group and the empty vector expression (T47D/HA-Vector) group according to the random number table method, with 18 mice in each group. All nude mice were inoculated with estradiol (E2) pellets 24 hours before the injection of tumor cells into both flanks. Then the two groups were inoculated with 150 μL of DMEM-F12 containing T47D/HA-PGRMC1和T47D/HA-Vector, respectively. When the mean tumor volume reached approximately 100 mm3, the two groups were divided into three subgroups, with 6 mice of each subgroups, including subcutaneous embedding sustained-release tablets of placebo (E2+placebo subgroup), norethinne (NET) (E2+NET subgroup) and progesterone (E2+progesterone subgroup). Tumor volumes were monitored for 45 d. Tumor tissue was analyzed by immunohistochemical staining for PGRMC1 and Ki-67 at the end of treatment. Results Compared with the T47D/HA-Vector group, tumor volumes in the T47D/HA-PGRMC1 group increased by 36%. In the T47D/HA-PGRMC1 group, compared with E2+placebo subgroup, E2+NET subgroup significantly promoted tumor growth, the difference was highly statistically significant (P < 0.01). There was no significant difference between E2+progesterone subgroup and E2+placebo subgroup (P > 0.05). In the T47D/HA-Vector group, there were no statistically significant differences between E2+placebo subgroup, E2+NET subgroup and E2+progesterone subgroup (all P > 0.05). In T47D/HA-PGRMC1 group, E2+NET subgroup showed positive expression of Ki-67. The comparison of expression levels of PGRMC1 and Ki-67 among 3 subgroups showed highly statistical significance (P < 0.01). The expressions of PGRMC1 and Ki-67 in E2+NET subgroup were significantly higher than those in E2+placebo subgroup and E2+progesterone subgroup, and the differences were statistically significant (all P < 0.05). There was no significant difference in the expression levels of PGRMC1 and Ki-67 between E2+placebo subgroup and E2+progesterone subgroup (all P > 0.05). There were no significant differences in the expression of PGRMC1 and Ki-67 among 3 subgroups of the T47D/HA-Vector group (all P > 0.05). Immunohistochemical results showed that PGRMC1 was positively correlated with Ki-67 expression (r = 0.839, P = 0.002). Conclusion It is the first found that E2+NET increases the tumor growth of human breast cancer cells that overexpress PGRMC1 but not with progesterone in vivo. The results are consistent with those of in vitro experiments.
|
|
|
|
|
|
[1] The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society [J]. Menopause，2017，24（7）：728-753.
[2] Lovre D，Peacock E，Katalenich B，et al. Conjugated Estrogens and Bazedoxifene Improve β Cell Function in Obese Menopausal Women [J]. J Endocr Soc，2019，3（8）：1583-1594．
[3] Kohn GE，Rodriguez KM，Hotaling J，et al. The history of estrogen therapy [J]. Sex Med Rev，2019，7（3）：416-421.
[4] Arriaga ME，Vajdic CM，Canfell K，et al. The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia： a pooled cohort study [J]. Int J Cancer，2019，145（9）：2383-2394.
[5] Beral V. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the million women study [J]. Lancet，2003，362：419-427.
[6] Fournier A，Berrino F，Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies：results from the E3N cohort study [J]. Breast Cancer Res Treat，2008，107（1）：103-111.
[7] Anderson GL，Chlebowski RT，Aragaki AK，et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy：extended follow-up of the Women′s Health Initiative randomised placebo-controlled trial [J]. Lancet Oncol，2012， 13（5）：476-486.
[8] Terzaghi L，Luciano AM，Dall′Acqua PC，et al. PGRMC1 localization and putative function in the nucleolus of bovine granulosa cells and oocytes [J]. Reproduction，2018， 155（3）：273-282.
[9] Ruan X，Gu M，Cai G，et al. Progestogens and PGRMC1-dependent breast cancer tumor growth：an in-vitro and xenograft study [J]. Maturitas，2019，123：1-8.
[10] Ruan X，Neubauer H，Yang Y，et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells [J]. Climacteric，2012，15（5）：467-472.
[11] Yeo W，Chan SL，Mo FK，et al. Phase Ⅰ/Ⅱ study of temsirolimus for patients with unresectable Hepatocellular Carcinoma（HCC）-a correlative study to explore potential biomarkers for response [J]. BMC Cancer，2015， 15：395.
[12] Roetker NS，Peng Y，Ashfaq A，et al. Adherence to Kidney Disease： Improving Global Outcomes Mineral and Bone Guidelines for Monitoring Biochemical Parameters [J]. Am J Nephrol，2019，49（3）：225-232.
[13] Kim JY，Kim SY，Choi HS，et al. Progesterone Receptor Membrane Component 1 suppresses the p53 and Wnt/β-catenin pathways to promote human pluripotent stem cell self-renewal [J]. Sci Rep，2018，8（1）：3048.
[14] Mohanmmed H，Russell IA，Stark R，et al. Progesterone receptor modulates ERα action in breast cancer [J]. Nature，2015，523（7560）：313-317.
[15] Zhao Y，Ruan X，Wang H，et al. The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone：A xenograft model [J]. Maturitas，2017，102：26-33.
[16] Ruan X，Zhao Y，Mueck AO，et al. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer [J]. Menopause，2017，24（2）：203-209.
[17] Ruan X，Schneck H，Schultz S，et al. Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells [J]. Gynecol Endocrinol，2012，28（11）：863-866.
[18] Samson M，Porter N，Orekoya O，et al. Progestin and breast cancer risk： a systematic review [J]. Breast Cancer Res Treat，2016，155（1）：3-12.
[19] Simin J，Tamimi R，Lagergren J，et al. Menopausal hormone therapy and cancer risk： An overestimated risk? [J]. Eur J Cancer，2017，84：60-68.
[20] Li X，Ruan X，Gu M，et al. PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells：estradiol vs. equilin vs. Ethinylestradiol [J]. Climacteric，2019， 22（5）：483-488. |
|
|
|
